[go: up one dir, main page]

AR110114A1 - ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS - Google Patents

ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS

Info

Publication number
AR110114A1
AR110114A1 ARP170103056A ARP170103056A AR110114A1 AR 110114 A1 AR110114 A1 AR 110114A1 AR P170103056 A ARP170103056 A AR P170103056A AR P170103056 A ARP170103056 A AR P170103056A AR 110114 A1 AR110114 A1 AR 110114A1
Authority
AR
Argentina
Prior art keywords
amyloid
piroglutamato
antigen
antibody
antibodies against
Prior art date
Application number
ARP170103056A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR110114A1 publication Critical patent/AR110114A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)

Abstract

La divulgación proporciona un anticuerpo o fragmentos de unión al antígeno de este que se une a péptidos amiloide-b que tienen piroglutamato en el tercer residuo (3pE Ab) y métodos para elaborar y usar el anticuerpo o fragmento de unión al antígeno de este, que incluyen el uso para formulaciones, administración y estuches. El anticuerpo y fragmentos de unión al antígeno de este y los métodos descritos son útiles para el diagnóstico, pronóstico y tratamiento de la enfermedad de Alzheimer u otras enfermedades relacionadas con b-amiloide.
ARP170103056A 2016-11-03 2017-11-03 ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS AR110114A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662416788P 2016-11-03 2016-11-03

Publications (1)

Publication Number Publication Date
AR110114A1 true AR110114A1 (es) 2019-02-27

Family

ID=60473574

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103056A AR110114A1 (es) 2016-11-03 2017-11-03 ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS

Country Status (11)

Country Link
US (3) US10519223B2 (es)
EP (1) EP3534937B1 (es)
JP (2) JP7071349B2 (es)
CN (1) CN109922826A (es)
AR (1) AR110114A1 (es)
AU (1) AU2017355596A1 (es)
CA (1) CA3041969A1 (es)
ES (1) ES2962767T3 (es)
MA (1) MA46704A (es)
TW (1) TW201827467A (es)
WO (1) WO2018083628A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110561B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
JP7207517B2 (ja) * 2019-03-01 2023-01-18 株式会社島津製作所 Ａｐｐ６６９－７１１の測定方法、及び測定用キット
BR112021019107A2 (pt) * 2019-03-26 2021-11-30 Janssen Pharmaceutica Nv Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3
WO2025037271A1 (en) 2023-08-17 2025-02-20 Janssen Pharmaceutica Nv Plasma assay for detecting cns-derived tau peptides
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule
CN118459582B (zh) * 2024-07-11 2024-11-15 苏州近岸蛋白质科技股份有限公司 一种抗焦谷氨酸修饰的β淀粉样蛋白抗体及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
JP5475994B2 (ja) * 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US20110182809A1 (en) 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
CN105481980A (zh) * 2008-07-21 2016-04-13 前体生物药物股份公司 诊断抗体测定
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
EP2576617B1 (en) * 2010-06-04 2016-04-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
PT3042917T (pt) * 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2015191825A1 (en) 2014-06-13 2015-12-17 Biogen Ma Inc. Methods for the detection and measurement of amyloid beta in biological samples
JP2018501482A (ja) * 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
EP3322723A2 (en) 2015-07-16 2018-05-23 Probiodrug AG Anti-pyroglutamated amyloid beta humanized antibodies
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TW201740954A (zh) 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
EP3249388A1 (en) 2016-05-23 2017-11-29 Raman Health Technologies, S.L Method for diagnosing alzheimer´s disease
CA3026598A1 (en) 2016-06-07 2017-12-14 Biogen International Neuroscience Gmbh Methods for treating alzheimer's disease
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
TWI669119B (zh) 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
WO2019040612A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES

Also Published As

Publication number Publication date
EP3534937B1 (en) 2023-09-27
CA3041969A1 (en) 2018-05-11
EP3534937C0 (en) 2023-09-27
JP7348987B2 (ja) 2023-09-21
US10851156B2 (en) 2020-12-01
CN109922826A (zh) 2019-06-21
US20210147528A1 (en) 2021-05-20
JP2019534010A (ja) 2019-11-28
TW201827467A (zh) 2018-08-01
ES2962767T3 (es) 2024-03-21
US20180142011A1 (en) 2018-05-24
US11673943B2 (en) 2023-06-13
WO2018083628A1 (en) 2018-05-11
US10519223B2 (en) 2019-12-31
JP2022115986A (ja) 2022-08-09
US20200165328A1 (en) 2020-05-28
JP7071349B2 (ja) 2022-05-18
MA46704A (fr) 2019-09-11
AU2017355596A1 (en) 2019-05-16
EP3534937A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
ECSP19005417A (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
MX2021001098A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
CL2022002670A1 (es) Anticuerpos contra amiloide-bcon piroglutamato y usos de estos (divisional solicitud 202102473).
CL2019000694A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal.
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
GT201200271A (es) Proteínas que se unen al tnf-a
CO2018014010A2 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
MX2018000505A (es) Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos.
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
MX2018000347A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2014003357A (es) Terapia basada en proteina y diagnostico de patalogia mediada por tau en la enfermedad de alzheimer.
UY37456A (es) Inmunoglobulinas y sus usos
PE20170768A1 (es) Anticuerpos de union a protofibrillas ab mejorados
MX2023011121A (es) Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
MX2025003354A (es) Anticuerpos que se unen a 5t4

Legal Events

Date Code Title Description
FB Suspension of granting procedure